Psychiatry
Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.
10 Nov, 2021 | 06:57h | UTCAntipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)
Commentary on Twitter
Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051
— P𝘧OL (@psychopharmacol) September 12, 2021
Adolescents’ recreational screen time doubled during pandemic, affecting mental health.
3 Nov, 2021 | 10:06h | UTCCommentary: Kids nearly doubled screen time during the pandemic, but there is something you can do about it – CNN
Commentary from the author on Twitter
🚨 New @UCSF study in @JAMAPediatrics 🚨
Recreational #ScreenTime in teens doubled to nearly 8⃣ hours per day during the #COVID19 #pandemic, excluding screen time for school.
⬆️ screen time linked to
⬇️ mental health
⬆️ stress
⬇️ social support🔗 https://t.co/04RhNIAh4r 📺 pic.twitter.com/f2PvETdFbF
— Jason Nagata, MD (@jasonmnagata) November 1, 2021
NICE Guideline | Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management.
31 Oct, 2021 | 20:03h | UTCCommentaries:
Chronic fatigue syndrome advice scraps exercise therapy – BBC
ME exercise therapy guidance scrapped by health watchdog Nice – The Guardian
Stimulant prescription linked to increased short-term risks of cardiovascular events in older adults.
29 Oct, 2021 | 09:47h | UTCAssessment of Stimulant Use and Cardiovascular Event Risks Among Older Adults – JAMA Network Open
Commentaries:
Stimulants Linked to Early Risk of CV Events in Elderly – TCTMD
Stimulants May Pose Short-Term Cardiovascular Risks in Older Adults – Psychiatric News Alert
RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.
28 Oct, 2021 | 10:22h | UTCCommentaries:
The TOGETHER Trial: COVID-19 and Fluvoxamine Take Two – REBEL EM
The antidepressant fluvoxamine can keep COVID-19 patients out of the hospital – ScienceNews
Related:
Commentary on Twitter
NEW in @LancetGH: Using SSRI #fluvoxamine to treat high-risk outpatients with early-diagnosed #COVID19 reduced the need for prolonged observation in an emergency setting or hospitalisation: largest trial to date. https://t.co/BVtMju74lp @TogetherTrial pic.twitter.com/F1FnZuyqdY
— The Lancet (@TheLancet) October 27, 2021
Brain fog can persist for months after COVID diagnosis.
28 Oct, 2021 | 10:13h | UTCAssessment of Cognitive Function in Patients After COVID-19 Infection – JAMA Network Open
Commentaries:
Brain fog can persist 8 months after COVID diagnosis – CIDRAP
M-A: The efficacy of pharmacotherapies for the treatment of borderline personality disorder is limited.
27 Oct, 2021 | 01:11h | UTC
RCT: The association of Varenicline and Nicotine patch was not better than Varenicline alone to increase smoking abstinence; there was also no difference between 24-week vs. 12-week treatment courses in abstinence rates.
24 Oct, 2021 | 23:45h | UTCEffects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial – JAMA (free for a limited period)
Editorial: Is There a Role for Combined Use of Varenicline and Nicotine Patch or Extended Treatment Duration to Enhance Smoking Cessation? – JAMA (free for a limited period)
Commentary: Varenicline Combo, Extension No Better for Quitting Smoking – HealthDay
Commentary on Twitter
Study findings do not support the use of combined varenicline plus nicotine patch therapy (vs varenicline monotherapy) or of extended treatment duration (24 vs 12 weeks) for smoking cessation https://t.co/XcQMQZgQb9
— JAMA (@JAMA_current) October 19, 2021
M-A: Clinical interventions for adults with comorbid alcohol use and depressive disorders.
24 Oct, 2021 | 23:39h | UTC
RCT: Mirtazapine not better than placebo for the treatment of agitation in people with dementia and was possibly associated with increased mortality (7 vs.1 deaths, difference not statistically significant; p=0·065).
22 Oct, 2021 | 10:19h | UTCCommentary: Common antidepressant should no longer be used to treat people with dementia – University of Exeter
The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.
21 Oct, 2021 | 09:48h | UTC
Systematic Review: Restricting access to poisons is associated with decreases in suicide by poisoning without an equivalent shift toward other methods.
20 Oct, 2021 | 09:48h | UTC
Commentary on Twitter
Important new study on suicide in @JAMAHealthForum. Restricting access to poisons is associated with reductions in suicide without an equivalent shift toward other methods. https://t.co/dINq3oIxvd pic.twitter.com/vEn9wOlprN
— David Juurlink (@DavidJuurlink) October 18, 2021
Cluster RCT: An exercise intervention may improve academic achievement among children.
19 Oct, 2021 | 09:45h | UTC
Commentary on Twitter
Physical inactivity is an important health concern worldwide. This study examined the effects of an exercise intervention on children’s academic achievement, cognitive function, physical fitness, and other health-related outcomes: https://t.co/Pdd0qZqYNN #Pediatrics pic.twitter.com/VkyPba3Sv2
— AAP CME Journals (@AAPJournals) October 18, 2021
M-A: Psychosocial and psychological interventions for relapse prevention in schizophrenia.
17 Oct, 2021 | 21:12h | UTC
Commentary on Twitter
An excellent SR/Network MA on #Psychosocial interventions for relapse prevention in #schizophrenia
Family interventions, family psychoeducation, & CBT are effective & must be prioritised in the care systems for patients with schizophrenia @TheLancetPsych https://t.co/d6xRw14fbT— 🌈 Rajesh Mohan @raj-psyc.bsky.social (@raj_psyc) October 16, 2021
RCT: Oxytocin does not improve social functioning in children with autism spectrum disorder.
14 Oct, 2021 | 09:52h | UTCOriginal study: Intranasal Oxytocin in Children and Adolescents with Autism Spectrum Disorder – New England Journal of Medicine
New Global Burden of Disease analyses show depression and anxiety among the top causes of health burden worldwide, and a significant increase due to the COVID-19 pandemic.
10 Oct, 2021 | 21:57h | UTCCommentaries:
Depression and anxiety disorders during the COVID-19 pandemic: knowns and unknowns – The Lancet
Covid crisis dramatically worsened global mental health, study finds – The Guardian
Commentary on Twitter (thread – click for more)
✨🆕–The #COVID19 pandemic led to a stark rise in depressive and anxiety disorders globally in 2020 w/women & younger people most affected, according to a new study by our researchers & collaborators published today in @TheLancet. #GBDstudy #MentalHealth
»https://t.co/qXEDzn3idV pic.twitter.com/4xsofBXyvS
— Institute for Health Metrics and Evaluation (IHME) (@IHME_UW) October 8, 2021
World Mental Health Day: prioritize social justice, not only access to care.
10 Oct, 2021 | 21:37h | UTCWorld Mental Health Day: prioritise social justice, not only access to care – The Lancet (free registration required)
Commentary on Twitter
"…under the wrong set of social circumstances, everyone is vulnerable to mental health problems."#WorldMentalHealthDay: prioritise social justice, not only access to care—a Comment by Soumitra Pathare @netshrink and colleagues. https://t.co/AwdSXo8y5H pic.twitter.com/Az6AB9vLmm
— The Lancet (@TheLancet) October 10, 2021
M-A: Accuracy of the Patient Health Questionnaire-9 for screening to detect major depression.
10 Oct, 2021 | 21:34h | UTCSee calculator: PHQ-9 (Patient Health Questionnaire-9)
Commentary on Twitter
This new study investigates the accuracy of the Patient Health Questionnaire-9 (PHQ-9), the most commonly used depression screening tool in general practice, for detecting major depression https://t.co/9WoI3MofWH
— The BMJ (@bmj_latest) October 10, 2021
Age at onset of mental disorders worldwide: large-scale meta-analysis of 192 epidemiological studies.
10 Oct, 2021 | 21:31h | UTC
Editorial: Brain health and its social determinants.
10 Oct, 2021 | 21:35h | UTCBrain health and its social determinants – The Lancet
Commentary on Twitter
Globally, action to tackle the social determinants of mental ill health—including poverty, racism, and discrimination—remains a low priority in too many countries.
On #WorldMentalHealthDay, read our Editorial: https://t.co/VRJkZ8kVn5#MentalHealth #WMHD2021 pic.twitter.com/hxvrCoMbt0
— The Lancet (@TheLancet) October 10, 2021
The German Guidelines for the treatment of anxiety disorders.
8 Oct, 2021 | 10:16h | UTC
Saying ‘person with schizophrenia,’ not ‘schizophrenic,’ can affect clinician beliefs, study finds.
1 Oct, 2021 | 10:05h | UTCOriginal article: It’s Time for Counselors to Modify Our Language: It Matters When We Call Our Clients Schizophrenics Versus People With Schizophrenia – Journal of Counseling & Development ($)
RCT: Maintenance vs. discontinuation of antidepressants in patients who felt well enough to discontinue antidepressant therapy.
30 Sep, 2021 | 10:22h | UTCMaintenance or Discontinuation of Antidepressants in Primary Care – New England Journal of Medicine
Commentaries:
Many can stop anti-depressants without relapse – BBC
Study highlights difficulty of stopping antidepressants – Associated Press
Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review.
30 Sep, 2021 | 10:07h | UTC
Commentary on Twitter
Review: Methylphenidate is effective both against the core ADHD symptoms (SMD=0.49; 0.35–0.64), and the emotion regulation deficits (SMD=0.34; 0.23–0.45) in adults with ADHD. Long-term AEs: decreased appetite, dry mouth, heart palpitations, agitation https://t.co/V73jPK58pL
— P𝘧OL (@psychopharmacol) September 25, 2021
M-A: Magnitude of the placebo response across treatment modalities used for treatment-resistant depression in adults.
29 Sep, 2021 | 10:04h | UTCInvited Commentary: Treatment-Resistant Depression—Resistant to Placebos as Well? – JAMA Network Open
Commentaries on Twitter
This systematic review and meta-analysis found that in studies of patients with treatment-resistant depression, the placebo effect was large and consistent despite the modality use. https://t.co/U6efJo7rJ8
— JAMA Network Open (@JAMANetworkOpen) September 24, 2021
Important systematic review study: The placebo effect in clinical trials of depression, even if treatment-resistant, is huge!
Magnitude of the Placebo Response Across Treatment-Resistant Depression in Adults https://t.co/ey2hIpE61r via @JAMANetworkOpen part of @JAMANetwork
— Yasser Ad-Dab'bagh 🦋@yasseraddabbagh.bsky.social (@yasseraddabbagh) September 25, 2021
Question
Why does research on 'treatment resistance' have such high placebo response?3 Answers
1)Research patients arent nearly as sick as patients in clinical practice
2)Research patients get much more attention than clinical patients
3)Research raises very high expectations https://t.co/f8CyTpKofV— Allen Frances (@AllenFrancesMD) September 26, 2021
(thread – click for more)
The paradox of "treatment resistance" in psychiatry that doesn't seem to generate much discussion: if the depression is so treatment resistant that we are considering things like invasive brain stimulation, how come it responds to "placebo" so robustly?/1https://t.co/oQOBPXtVXO
— Awais Aftab (@awaisaftab) September 26, 2021


